Episode Details

Back to Episodes

Can an Implant-Free Laser Procedure Free Glaucoma Patients From Eye Drops? New 2-Year ELIOS Results

Published 1 month, 3 weeks ago
Description

This audio article is from VisualFieldTest.com.

Read the full article here: https://visualfieldtest.com/en/can-an-implant-free-laser-procedure-free-glaucoma-patients-from-eye-drops-new-2-year-elios-results

Test your visual field online: https://visualfieldtest.com

Support the show so new episodes keep coming: https://www.buzzsprout.com/2563091/support

Excerpt:

Can an Implant-Free Laser Procedure Free Glaucoma Patients From Eye Drops? New 2-Year ELIOS Results Bottom line The new 24-month ELIOS excimer laser trabeculostomy results are encouraging—but they answer a narrower question than many headlines suggest. The study shows that cataract surgery combined with ELIOS can produce a sustained reduction in unmedicated eye pressure and allow many patients to stop glaucoma drops for at least two years. In the pivotal study, mean unmedicated diurnal eye pressure fell from approximately 24.5 millimeters of mercury at baseline to 16.8 millimeters of mercury at 24 months, and 82.0% of patients were medication-free around month 23. Gallardo et al., 24-month pivotal study () However, the central limitation is important: there was no concurrent cataract-surgery-only control group. The trial was a prospective, single-arm study that compared its results with historical performance goals derived from earlier minimally invasive glaucoma surgery trials. My interpretation is: ELIOS plus cataract surgery works as a combined treatment. It probably provides additional pressure lowering beyond cataract surgery alone. The most reasonable estimate of the additional ELIOS effect at 24 months is approximately 1.5 to 2.5 millimeters of mercury, with a plausible range of roughly 1 to 3 millimeters of mercury. The medication-free benefit may be real and clinically valuable, but the exact size of that benefit is less certain without a randomized control arm. ELIOS appears best suited to patients with mild-to-moderate primary open-angle glaucoma who already need cataract surgery. It should not be viewed as a replacement for trabeculectomy or tube surgery in patients needing an eye pressure below 12 millimeters of mercury, or in many patients with advanced glaucoma. The original paper was published online on September 8, 2026, and the two-year results were presented at the European Society of Cataract and Refractive Surgeons Congress in London from September 10 through September 14, 2026. () What is ELIOS? ELIOS is an implant-free form of excimer laser trabeculostomy. Instead of leaving a stent inside the eye, the procedure uses a 308-nanometer xenon chloride excimer laser to create small openings through the trabecular meshwork, the eye’s main drainage tissue. These openings are intended to provide a more direct route for fluid to enter Schlemm’s canal and then reach the eye’s natural collector channels. The current ELIOS treatment creates: 10 microchannels Each approximately 210 micrometers in diameter Across approximately 90 to 110 degrees of the nasal trabecular meshwork After cataract removal and placement of an intraocular lens The procedure is performed through a small corneal incision under gonioscopic visualization. It is described as nonthermal photoablation, meaning that tissue is removed by breaking molecular bonds rather than by burning or coagulating tissue. () The 2026 pivotal study: exact design Study design The pivotal trial was: Prospective Multicenter Nonrandomized Single-arm Conducted under a United States investigational device exemption Registered as NCT04899063 Conducted at 20 United States sites Treatment period: approximately June 2021 through July 2023 Published as a 24-month report in Ophthalmology Glaucoma The study incl

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us